Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Widening access to isotretinoin in primary care: an evaluation of New Zealand national dispensing data for isotretinoin for acne, 2008-2023.

BMJ open·2025
Same author

Over and under? Ethnic inequities in community antibacterial prescribing.

The New Zealand medical journal·2019
Same author

Te Wero tonu-the challenge continues: Māori access to medicines 2006/07-2012/13 update.

The New Zealand medical journal·2018
Same author

Response to Cameron et al "Mind the graph" Semin Oncol. 2018.

Seminars in oncology·2018
Same author

The Zero Carbon Bill and the health of New Zealanders-help shape this crucial health law now.

The New Zealand medical journal·2018
Same author

Response to letter to the editor on 'Mind the gap'.

Seminars in oncology·2018

Related Experiment Video

Updated: May 24, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

National prescribing data for dabigatran

Scott Metcalfe, Peter Moodie

    The New Zealand Medical Journal
    |March 20, 2012
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
    10:26

    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

    Published on: June 2, 2015

    Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
    06:55

    Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

    Published on: January 8, 2020

    Related Experiment Videos

    Last Updated: May 24, 2026

    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
    23:33

    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

    Published on: February 28, 2012

    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
    10:26

    A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

    Published on: June 2, 2015

    Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
    06:55

    Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

    Published on: January 8, 2020